Revive Therapeutics Retained Mi3 Communications for Investor Relations Services
March 28 2018 - 4:30PM
Revive Therapeutics Ltd. ("
Revive" or the
“Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on
the research, development and commercialization of novel
cannabinoid solutions, announced that is has received notice from
the TSX-V accepting an arm’s length Investor Relations Agreement
(the “Agreement”) entered into with Mi3 Communications Financières
Inc. (the “Consultant”) of Montreal, Quebec, with an effective date
of January 2, 2018. The principal of the Consultant is Mario
Drolet.
Under the terms of the Agreement, the Consultant
will carry out services on behalf of the Company in Eastern Canada,
which services include, but are not limited to, communication of
all news releases and information on the Company, including
technical notes, posting on Consultant’s Twitter and Facebook, and
assisting the Company at PR roadshows across 12 cities in
Canada. As consideration for these services, the Company
agreed to pay to the Consultant a monthly consideration of C$3,000,
plus reimbursement of approved expenses, for a period of three
months commencing January 2, 2018. Pursuant to the Policies
of the TSX-V, the Company has internal policies and procedures in
place to monitor investor relations activities and to ensure
compliance with all applicable Securities Laws, Regulations and
Policies and Policies of the TSX-V.
About Revive Therapeutics
Ltd.
Revive Therapeutics Ltd. (TSX
VENTURE:RVV)(OTCQB:RVVTF) is focused on the research, development
and commercialization of novel therapies and technologies for the
medical cannabis and cannabinoid-based pharmaceutical markets.
Additional information on Revive is available at
www.ReviveThera.com.
REVIVE THERAPEUTICS LTD. CAUTIONARY NOTE
REGARDING FORWARD-LOOKING STATEMENTS
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
This news release includes certain information
and statements about management's view of future events,
expectations, plans and prospects that constitute "forward-looking
information" that involves known and unknown risks and
uncertainties, which are not comprised of historical facts, and
most of which are beyond the control of Revive. Forward-looking
statements include estimates and statements that describe Revive’s
future plans, objectives or goals, including words to the effect
that Revive or its management expects a stated condition or result
to occur. Forward-looking statements may be identified by such
terms as "believes", "anticipates", "intends", "expects",
"estimates", "may", "could", "would", "will", or "plan", and
similar expressions. Specifically, forward-looking statements in
this news release include, without limitation, statements
regarding: the granting of a patent for Bucillamine for the
treatment of gout; the potential efficacy and commercial viability
of Bucillamine for treatment of gout and Bucillamine for the
treatment of Cystinuria; expansion of the Bucillamine clinical
testing program; the Company's drug research and development, and
commercialization plans; the Company’s research, development and
commercialization plans for plant-based therapies, including
cannabinoids; the timing of operations; and estimates of market
conditions. These statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results or
events, performance, or achievements of Revive to differ materially
from those anticipated or implied in such forward-looking
statements. Since forward-looking statements are based on
assumptions and address future events and conditions, by their very
nature they involve inherent risks and uncertainties. The Company
believes that the expectations reflected in these forward-looking
statements are reasonable, but there can be no assurance that
actual results will meet management's expectations. In formulating
the forward-looking statements contained herein, management has
assumed: that business and economic conditions affecting Revive
will continue substantially in the ordinary course and will be
favourable to Revive; that clinical testing results will justify
commercialization of the Company's drug candidates; that Revive
will be able to obtain all requisite regulatory approvals to
commercialize its drug candidates; that such approvals will be
received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its drug
repurposing candidates on favourable terms. Although these
assumptions were considered reasonable by management at the time of
preparation, they may prove to be incorrect and no assurance can be
given that such events will occur in the disclosed time frames or
at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking
statements include: uncertainties associated with obtaining
regulatory approval to perform clinical trials and market products;
the need to establish additional corporate collaborations,
distribution or licensing arrangements; the Company's ability to
raise additional capital if and when necessary; intellectual
property disputes; increased competition from pharmaceutical and
biotechnology companies; changes in equity markets, inflation, and
changes in exchange rates; and other factors as described in detail
in Revive's Management's Discussion & Analysis for the period
ended June 30, 2017 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com). Given these risks and
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as
required by law, Revive disclaims any intention and assumes no
obligation to update or revise any forward-looking statements to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking statements or otherwise.
Contact:
Revive Therapeutics Ltd.Craig LeonChief
Executive OfficerRevive Therapeutics Ltd.Tel: (416) 272-5525Email:
craig@revivethera.comWebsite: www.revivethera.com
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Apr 2023 to Apr 2024